Back Hepatitis B Hepatitis B Topics HBV Treatment CROI 2013: Dually Active Antiretroviral Therapy Protects Against Primary Hepatitis B Infection

CROI 2013: Dually Active Antiretroviral Therapy Protects Against Primary Hepatitis B Infection


Use of antiretroviral therapy (ART) that includes drugs active against both hepatitis B virus (HBV) and HIV reduces the risk that HIV positive people will become infected with HBV -- in effect acting as HBV PrEP -- according to a study presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this week in Atlanta.

Approximately 6% to 10% of people with HIV are also infected with HBV, and coinfection is associated with more rapid liver disease progression than HBV monoinfection.

Although guidelines recommend that people with HIV be vaccinated against HBV, many do not finish the vaccine series or do not fully respond to immunization and therefore remain susceptible to infection.

Yet the rate of new HBV infections at Onze Lieve Vrouwe Gasthuis -- the largest HIV clinic in Amsterdam -- has recently been very low, leading Kees Brinkman and colleagues to ask whether antiretroviral drugs with dual activity against HIV and HBV might have contributed to a reduction in the likelihood of primary, or initial, hepatitis B.

These dually active agents include tenofovir (Viread, also in the Truvada, Atripla, Complera, and Stribild coformulations), lamivudine (Epivir or 3TC), and emtricitabine (Emtriva or FTC).

Out of a cohort of nearly 3000 people seen at the clinic (2280 of them men who have sex with men [MSM]), investigators retrospectively selected 350 individuals with serological markers indicating that they were uninfected but susceptible to HBV infection, and who had subsequent samples available for testing to see if their status changed.


  • At baseline, 1498 participants (51%) were HBV infected, 389 people (13%) were vaccinated, and 871 people (30%) -- including 590 MSM -- were HBV susceptible.
  • Looking just at the initially susceptible group, second samples showed that 530 (61%) -- including 349 MSM -- remained susceptible, 171 (20%) were vaccinated, and 35 (4%) were newly HBV infected.
  • 33 of the people with new HBV infections were MSM, 1 was a heterosexual man, and 1 was a woman.
  • People taking no dually active antiretroviral drugs became infected with HBV significantly sooner than those who did so.
  • People taking HBV-active therapy without tenofovir became infected sooner than those who included tenofovir (most all tenofovir users were also taking lamivudine or emtricitabine).
  • Based on these findings, the researchers concluded that incident or new HBV infections were indeed "rare." The 35 HBV infections in this study compared with more than 200 cases of acute hepatitis C virus infection in this population since 2002.

"HBV-active combination ART protects against primary HBV infection," acting as HBV pre-exposure prophylaxis (PrEP), the investigators concluded, and tenofovir-containing ART is more protective than regimens with lamivudine as the only HBV-active drug.

"The necessity to (re)vaccinate against HBV is reduced for patients receiving these drugs," they suggested.



M Heuft, G van den Berk, T Smissaert, K Brinkman, et al. Protective Effect of Hepatitis B Virus–active cART against Primary Hepatitis B Virus Infection. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3-6, 2013. Abstract 33.